A股異動 | 智飛生物(300122.SZ)漲超6% 中國科研團隊稱其參與研發的新冠疫苗對南非變異株有效
格隆匯2月3日丨智飛生物(300122.SZ)漲超6%,報179.59元,高見182元創近半年來新高,總市值2873.44億元。中國疾控中心高福等剛剛在bioRxiv發佈國產滅活新冠疫苗(北京生物製品研究所BBIBP-CorV滅活新冠疫苗)和正在開展3期臨牀試驗的國產重組蛋白亞單位新冠疫苗(智飛生物與中國科學院聯合開發的ZF2001重組蛋白亞單位新冠疫苗)對南非新變種的保護效果。結果顯示,雖然這兩種疫苗接種者血清對南非新變種的中和效果稍有下降,但是依然保留大部分中和活性,提示這兩種疫苗對南非新變種依然有保護效果。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.